Cite
Landen JW, Cohen S, Billing CB, et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y). 2017;3(3):339-347doi: 10.1016/j.trci.2017.04.003.
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J. H., Jack, C. R., Kantarci, K., Schwartz, P. F., Duggan, W. T., Zhao, Q., Sprenger, K., Bednar, M. M., & Binneman, B. (2017). Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimer's & dementia (New York, N. Y.), 3(3), 339-347. https://doi.org/10.1016/j.trci.2017.04.003
Landen, Jaren W, et al. "Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy." Alzheimer's & dementia (New York, N. Y.) vol. 3,3 (2017): 339-347. doi: https://doi.org/10.1016/j.trci.2017.04.003
Landen JW, Cohen S, Billing CB, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. PMID: 29067341; PMCID: PMC5651443.
Copy
Download .nbib